Japanese Journal of Pharmacology 1996: Vol 71 Index

5 Pages·1996·0.22 MB·English

AUTHOR INDEX
Volume 71 • 1996
Abe, A. See Ozaki, H. Antinarcotic activity of majonoside-R2 345
Abe, M. See Nagura, J.
Adachi, K. See Majima, M. Ikemura, T., Sasaki, Y., Ishii, H. and Ohmori, K.
Akuzawa, S. See Nishida, A. KW-4679 inhibits tachykinin release 179
Aniya, Y., Uehara, N., Ishii, C., Suenaga, T., Wada, N., Imaizumi, Y. See Ishii, Y.
Matsuzaki, T. and Sakanashi, M. - See Nagano, N.
NO formation from nitrates 101 Imanishi, M. See Ebara, T.
Araki, H. See Yamashita, K. Inatomi, N., Sato, F., Marui, S., Itoh, Z. and Omura, S.
Mechanisms of EM574 and motilin action 29
Baba, A. See Kitanaka, J. Inoue, H., Nagata, N., Shibata, S. and Koshihara, Y.
Ban, T. See Sada, H. Capsaicin and glycyrrhetinic acid derivatives 281
Bolton, T.B. See Ito, S. Ishii, C. See Aniya, Y.
Ishii, H. See Ikemura, T.
Chachin, M., Shimohama, S., Kunugi, Y.U. and Taniguchi, T. Ishii, Y., Muraki, K., Kurihara, A., Imaizumi, Y.
PKC mRNA levels in Alzheimer’s disease 175 and Watanabe, M.
Chairungsrilerd, N. See Furukawa, Ken-ichi Sematilide on Ik in guinea pig atrium 361
Chess-Williams, R. See Furukawa, Katsuo Ito, S. and Bolton, T.B.
Chiba, S. See Lakhe, M. IPs-induced Ca^^ release and K’^ current I
Chikahisa, L. See Okazaki, E. Itoh, Z. See Inatomi, N.
Chikahisa, L., Oyama, Y., Okazaki, E. and Noda, K. - See Iwanaga, Y.
Cell viability and cellular glutathione 299 Iwanaga, Y., Miyashita, N., Saito, T., Morikawa, K. and Itoh, Z.
Chikai, T. See Uchida, K. Gastroprokinetic effect of itopride 129
Corbett, R. See Seeman, P. Iwao, H. See Ebara, T.
- See Matsuura, T.
Dokmeci, D. See Karadag, ^.H. Iwata, S., Shimizu, T., Nomoto, M. and Fukuda, T.
Dokmeci, 1. See Karadag, ^.H. Upregulation of Dj-receptor 255
Due, N.M. See Huong, N.T.T.
Kanemaru, K. See Okazaki, E.
Ebara, T., Miura, K., Matsuura, T., Imanishi, M., Yamano, Y., Kaneto, H. See Nakao, K.
Kim, S. and Iwao, H. - See Tokuyama, S.
PAF and PG in rat endotoxic shock 247 Kanoh, H. See Motoie, H.
Egashira, T. See Goto, S. Karadag, Q.H., Ulugol, A., Dokmeci, D. and Dokmeci, i.
Role of Hi-receptors and morphine in MES 109
Fujii, T. See Morimoto, H. Karaki, H. See Ozaki, H.
Fujikura, T. See Motoie, H. -See Trongvanichnam, K.
Fujimura, A. See Sasaki, M. Kataoka, Y. See Yamashita, K.
Fukuchi, I. See Kinoshita, K. Katori, M. See Majima, M.
Fukuda, T. See Iwata, S. Katsuki, H. See Nakagami, Y.
Furukawa, Katsuo, Chess-Williams, R. and Uchiyama, T. Katsumata, O. See Majima, M.
aiB-Adrenoceptor subtypes in rabbit CCP 325 Kawabata, M. See Nishibori, M.
Furukawa, Ken-ichi, Shibusawa, K., Chairungsrilerd, N., Ohta, T., Kawamuki, K. See Motoie, H.
Nozoe, S. and Ohizumi, Y. Kawashima, K. See Kinoshita, K.
A novel inhibitor of Ca^^-pumping ATPase 337 Kawashima, Y. See Kinoshita, K.
Furukawa, Y. See Lakhe, M. Kim, S. See Ebara, T.
- See Matsuura, T.
Gomita, Y. See Sato, Tomoaki Kimura, L, Okabe, M., Ogasawara, M. and Kimura, M.
Goto, S., Egashira, T., Wada, Y., Takayama, F. and Yamanaka, Y. Competence effect of bFGF on aortic EC 21
Fluvoxamine and 5-HT system in monkey 291 Kimura, M. See Kimura, 1.
Kinoshita, K., Kawashima, K., Kawashima, Y., Fukuchi, I.,
Hachisu, M. See Nagura, J. Yamamura, M. and Matsuoka, Y.
Hamano, S. See Ohnota, H. ACh release and turnover by TA-0910 139
Hamaoka, S. See Sato, Tomoaki Kinoshita, M. See Ozaki, H.
Haruna, K. See Ohmori, H. Kinukawa, M. See Ohnota, H.
Hikida, M. See Ohmori, H. Kishimoto, T. See Ohmori, H.
Hirose, M. See Lakhe, M. Kitamura, T. See Ohnota, H.
Honda, K. See Koizumi, T. Kitanaka, J., Takuma, K., Kondo, K. and Baba, A.
Hori, M. See Ozaki, H. Prostanoid-induced glial Ca^^ signaling 85
Hui, C. See Nagura, J. Kizuki, K. See Majima, M.
Huong, N.T.T., Matsumoto, K., Yamasaki, K., Due, N.M., Koizumi, T., Saita, Y., Miyake, A., Nishida, A., Yazawa, H.
Nham, N.T. and Watanabe, H. and Honda, K.
Author Index
VI
YM022 as human CCKb antagonist 307 and Saeki, K.
Kondo, J. See Takano, M. Affinity purification of MIF 259
Kondo, K. See Kitanaka, J. Nishida, A., Uchida-Kobayashi, A., Takemoto, Y., Akuzawa, S.
Konno, F. See Nagura, J. and Miyata, K.
Koshihara, Y. See Inoue, H. Gastrin and acid secretion in rats 223
Kunugi, Y.U. See Chachin, M. Nishida, A. See Koizumi, T.
Kurihara, A. See Ishii, Y. Niwa, M. See Yamashita, K.
Noda, K. See Chikahisa, L.
Lakhe, M., Furukawa, Y., Yonezawa, T., Nagashima, Y., Nomoto, M. See Iwata, S.
Hirose, M. and Chiba, S. Nomura, Y. See Uchida, K.
Cardiac effects of U-92032 333 Nozoe, S. See Furukawa, Ken-ichi
Majima, M., Adachi, K., Ohno, T., Ogino, M., Saito, M., Ogasawara, M. SeeKimura, I.
Kizuki, K., Katsumata, O., Yamashina, S. and Katori, M. Ogata, S. See Motoie, H.
Kallikrein and oxytocin in SHR 11 Ogino, M. See Majima, M.
Marui, S. See Inatomi, N. Ohizumi, Y. See Furukawa, Ken-ichi
Matsuda, A. See Morimoto, H. Ohmori, H., Haruna, K., Okumura, A., Kishimoto, T.
Matsuda, T. See Tsushima, H. and Hikida, M.
Matsuki, N. See Toyoda, M. Subconjunctival immunization of mice 265
Matsumoto, K. See Huong, N.T.T. Ohmori, K. See Ikemura, T.
Matsunaga, K. See Sato, Tomoaki Ohno, T. See Majima, M.
Matsuoka, Y. See Kinoshita, K. Ohnota, H., Kitamura, T., Kinukawa, M., Hamano, S.,
Matsuura, T. See Ebara, T. Shibata, N., Miyata, H. and Ujiie, A.
Matsuura, T., Yukimura, T., Kim, S., Miura, K. and Iwao, H. Efficacy of KAD-1229 in NIDDM rats 315
Effects of ET antagonists on BP and RBF 213 Ohori, M. See Morimoto, H.
Matsuzaki, T. See Aniya, Y. Ohta, T. See Furukawa, Ken-ichi
Meade, C.J., Muacevic, G., Ward, P. and Soyka, R. Oishi, R. See Sato, Tomoaki
Pulmonary pharmacology of DT-TX 30 SE 119 Oka, T. and Yoshimura, N.
Mitsui-Saito, M. See Ozaki, H. Immunosuppressive therapy in organ transplantation 89
- See Trongvanichnam, K. Okabe, M. SeeKimura, I.
Miura, K. See Ebara, T. Okamoto, H. See Takano, M.
- See Matsuura, T. Okazaki, E. See Chikahisa, L.
Miyake, A. See Koizumi, T. Okazaki, E., Chikahisa, L., Kanemaru, K. and Oyama, Y.
Miyashita, N. See Iwanaga, Y. Effect of H2O2 on intracellular Ca^^ 273
Miyata, H. See Ohnota, H. Okumura, A. See Ohmori, H.
Miyata, K. See Nishida, A. Omura, S. See Inatomi, N.
Mori, M. See Tsushima, H. Oyama, Y. See Chikahisa, L.
Mori, S. See Nishibori, M. - See Okazaki, E.
Morikawa, K. See Iwanaga, Y. Ozaki, H. See Trongvanichnam, K.
Morimoto, H., Matsuda, A., Ohori, M. and Fujii, T. Ozaki, H., Abe, A., Uehigashi, Y., Kinoshita, M., Hori, M.,
N-type Ca^^ channels in sensory nerves 161 Mitsui-Saito, M. and Karaki, H.
Motoie, H., Kanoh, H., Ogata, S., Kawamuki, K., Shikama, H. Iloprost on vascular smooth muscle 231
and Fujikura, T.
Prevention of bone loss by YM175 in dogs 239 Sada, H., Ban, T. and Sperelakis, N.
Muacevic, G. See Meade, C.J. Taurine and Na^ channel kinetics 147
Muraki, K. See Ishii, Y. Saeki, K. See Nishibori, M.
Saita, Y. See Koizumi, T.
Nagano, N., Imaizumi, Y. and Watanabe, M. Saito, H. See Nakagami, Y.
Quinacrine on smooth muscle Ca^^ channel 51 -See Toyoda, M.
Nagashima, Y. See Lakhe, M. Saito, M. See Majima, M.
Nagata, N. See Inoue, H. Saito, T. See Iwanaga, Y.
Nagura, J., Hui, C., Yamamoto, M., Yasuda, S., Abe, M., Sakanashi, M. See Aniya, Y.
Hachisu, M. and Konno, F. Sasaki, M. and Fujimura, A.
Effects of ME3221 in aged-SHRSP 39 Lomefloxacin and drug interaction 263
Nakagami, Y., Saito, H. and Katsuki, H. Sasaki, Y. See Ikemura, T.
Cytotoxicity of 3-hydroxykynurenine 183 Sato, F. See Inatomi, N.
Nakamura, F. See Tokuyama, S. Sato, Tomoaki, Suemaru, K., Matsunaga, K., Hamaoka, S.,
Nakao, H. See Uchida, K. Gomita, Y. and Oishi, R.
Nakao, K. See Tokuyama, S. L-Dopa potentiation by Hj antagonists 81
Nakao, K., Takahashi, M. and Kaneto, H. Satoh, Takashi See Uchida, K.
Central Katp channel and SIA 269 Seeman, P., Corbett, R., Nam, D. and Van Tol, H.H.M.
N.-Nakashima, M. See Yamashita, K. Dopamine and serotonin receptors 187
Nakaya, N. See Nishibori, M. Shibata, N. See Ohnota, H.
Nam, D. See Seeman, P. Shibata, S. See Inoue, H.
Nham, N.T. See Huong, N.T.T. Shibusawa, K. See Furukawa, Ken-ichi
Nishibori, M., Nakaya, N., Mori, S., Kawabata, M., Tahara, A. Shikama, H. See Motoie, H.
Author Index VII
Shimizu, T. See Iwata, S. Cholesterol on bile acid in germ-free rat 113
Shimohama, S. See Chachin, M. Uchida-Kobayashi, A. See Nishida, A.
Soyka, R. See Meade, C.J. Uchiyama, T. See Furukawa, Katsuo
Sperelakis, N. See Sada, H. Uehara, N. See Aniya, Y.
Suemaru, K. See Sato, Tomoaki Uehigashi, Y. See Ozaki, H.
Suenaga, T. See Aniya, Y. Ujiie, A. See Ohnota, H.
Ulugbl, A. See Karadag, C^.H.
Tahara, A. See Nishibori, M.
Takahashi, M. See Nakao, K. Van Tol, H.H.M. See Seeman, P.
See Tokuyama, S.
Takano, M., Kondo, J., Yayama, K. and Okamoto, H. Wada, N. See Aniya, Y.
Kininogen expression in human fibroblasts 341 Wada, Y. See Goto, S.
Takase, H. See Uchida, K. Ward, P. See Meade, C.J.
Takayama, F. See Goto, S. Watanabe, H. See Huong, N.T.T.
Takemoto, Y. See Nishida, A. Watanabe, M. See Ishii, Y.
Takeuchi, N. See Uchida, K. - See Nagano, N.
Takuma, K. See Kitanaka, J.
Tanabe, H. See Yamashita, K. Yamamoto, M. See Nagura, J.
Taniguchi, T. See Chachin, M. Yamamura, M. See Kinoshita, K.
Taniyama, K. See Yamashita, K. Yamanaka, Y. See Goto, S.
Tokuyama, S., Nakamura, F., Nakao, K., Takahashi, M. Yamano, Y. See Ebara, T.
and Kaneto, H. Yamasaki, K. See Huong, N.T.T.
Conditioned place preference of dihydroetorphine 357 Yamashina, S. See Majima, M.
Toyoda, M., Saito, H. and Matsuki, N. Yamashita, K., Kataoka, Y., N.-Nakashima, M., S.-Yamashita, Y.,
No effect of carbon monoxide on learning 205 Tanabe, H., Araki, H., Niwa, M. and Taniyama, K.
Trongvanichnam, K., Mitsui-Saito, M., Ozaki, H. and Karaki, H. TTC-909 and ischemic hippocampal injury 351
ISDN on vascular smooth muscle contraction 167 S.-Yamashita, Y. See Yamashita, K.
Tsushima, H., Mori, M. and Matsuda, T. Yasuda, S. See Nagura, J.
Neural connections between the bilateral SON 73 Yayama, K. See Takano, M.
Neuropeptides in the PVN and SON 61 Yazawa, H. See Koizumi, T.
Yonezawa, T. See Lakhe, M.
Uchida, K., Satoh, Takashi, Chikai, T., Takase, H., Nomura, Y., Yoshimura, N. See Oka, T.
Nakao, H. and Takeuchi, N. Yukimura, T. See Matsuura, T.
SUBJECT INDEX
Volume 71 • 1996
Acetylcholine release 139 Conditional place preference 357 3-Hydroxykynurenine 183
Acetylcholine turnover 139 Conscious dog 129 5-Hydroxytryptamine uptake 291
Acid secretion 223 Corpus cavernosum penis (rabbit) 325 Hypoglycemic agent 315
Adrenergic neuron 73 Cyclooxygenase 247 Hypothalamus 73
a IB-Adrenoceptor subtype 325 Cytotoxicity 299
Aging 113 Iloprost 231
Airway 161 Delayed rectifier current 361 Immunosuppressive agent 89
Alzheimer’s disease 175 Diabetes mellitus 315 Indo-1 1
Analgesia 269 Diabetic complication 315 Inhibitor 119
Angiotensin ATi-receptor antagonist 39 Dietary calcium restriction 239 Inositol 1,4,5-trisphosphate 1
Anticonvulsive effect 109 Dietary cholesterol 113 Intracellular Ca^^ 273
Anti-dinitrophenyl IgE 265 Dihydroetorphine 357 Ischemia-related delayed neuronal death
Antidiuresis 61,73 Diuresis 11 351
Anti-emetic action 129 L-Dopa 81 Isosorbide dinitrate 167
Antinociception 345 Dopamine D4-receptor 187 Itopride 129
Antipsychotic drug 187 Dopamine uptake 81
Aorta (guinea pig) 231 Drug interaction 263 channel 269
Aorta (rat) 167 current 1, 361
Aortic endothelial cell (rat) 21 Ear edema 281 KAD-1229 (calcium (2S)-2-benzyl-3-(cis-hexa-
Astrocyte 85 Edema 281 hydro-2-isoindolinylcarbonyl)propionate
ATP-sensitive channel 269 Electroconvulsive shock 109 dihydrate) 315
ATPase 337 EM574 (de(N-methyl)-Ar-isopropyl-8,9- Ki-67 antigen 21
Atrium (guinea pig) 361 anhydroerythromycin A 6,9-hemiacetal) Kininogen 341
29 KW-4679 ((Z)-l l-[(3-dimethylamino)propyl-
Basic fibroblast growth factor 21 Endothelial cell 21 idene]-6,ll-dihydrodibenz[b,e]oxepin-
Bile acid metabolism 113 Endothelin-1 213 2-acetic acid monohydrochloride) 179
Bisphosphonate 239 Endotoxin 247
Bone mineral density 239 Enteric nervous system 29 Learning 205
BQ-788 (N-c«-2,6-dimethylpiperidinocar- Ethidium 299 Lomefloxacin 263
bonyl-L-;'-methylleucyl-D-1 -methoxycar- Lung 119
bonyltryptophanyl-D-norleucine) 213 Fibroblast 341 Lymphokine 89
Brain (bovine) 259 Fibroblast growth factor 21
Brain (monkey) 291 Flow cytometer 273 Macrophage migration inhibition
Flow cytometry 21 factor/glycosylation inhibiting factor
Ca^^ (intracellular) 273 Fluvoxamine 291 259
Ca^^ channel 51 FR139317 ((R)2-[(R)-2[(S)-2[[ 1 -(hexahydro- Majonoside-R2 345
Ca^^ channel (L-type) 333 l//-azepinyl)]carbonyl]amino-4- a-Mangostin 337
Ca^’^ channel (N-type) 161 methylpentanoyl]amino-3-[3-( 1 -methyl- ME3221 (3-methoxy-2,6-dimethyl-4-[[2'-(l//-
Ca^^ channel (T-type) 333 l//-indoyl)]propionyl]amino-3-(2- tetrazol-5-yl)-l,l'-biphenyl-4-yl]methoxy]
Ca^’^ mobilization 85, 307 pyridyl)propionic acid) 213 pyridine) 39
Ca^^-pumping ATPase 337 5-Methylurapidil 325
Ca^*-transient 1 GABAA-receptor 345 Microdialysis 139
Caged inositol 1,4,5-trisphosphate 1 Gastric motility 129 Morphine 109,357
Calcium restriction 239 Gastrin receptor 223 Motilin 29
cAMP 231 Gastroprokinetic 129 mRNA 175
Capsaicin 281 Germ-free rat 113
Carbon monoxide 205 Glibenclamide 269 Na* channel 147
Cardiac ventricle 51 Glutathione 299 Natriuresis 11
Catalepsy 187 Glutathione S-transferase 101 Neuronal death 351
Chenodeoxycholic acid 113 Glycosylation inhibiting factor 259 Nitrate 101
5-Chloromethylfluorescein 299 Glycyrrhetinic acid derivative 281 Nitric oxide 101, 205
Cholecystokinin-8 307 Non-insulin-dependent diabetes mellitus
Cholecystokinine/gastrin receptor 307 Hemodynamics 247 315
Cholesterol 113 Histamine 109 Nonprotein thiol 273, 299
Cholic acid/chenodeoxycholic acid ratio Histamine Hi-receptor 109 Norepinephrine 73
113 Histamine H2-receptor 223
Cholinergic neuron 29, 223 Histamine Hi-receptor antagonist 81 Organ transplantation 89
Chronic treatment 167 Huntington’s disease 183 Outward current 1
Cisapride 29 Hydrogen peroxide 273 Ovariectomy 239
Clozapine 187 6-Hydroxydopamine 255 Oxidative stress 273
Subject Index IX
Oxytocin 11 Sematilide 361 Transplantation (organ) 89
Sensory nerve 161
Paraventricular nucleus 61 Serotonin 2-receptor 187 U-92032 ((7-((bis-4-fluorophenyl)methyl)-1 -
Parkinsonism 187 Serpin 259 piperazinyl)-2-2(2-hydroxyethylamino)-4-
Parotic lymph node 265 Smooth muscle 51 (1 -methylethyl)-2,4,6-cycloheptatrien-1 -
Paroxetine binding 291 Spatial learning 205 one) 333
Passive avoidance learning 205 Spontaneously hypertensive rat 11 Upregulation 255
Patch clamp 1 Stable expression 307
Penis 325 Streptozotocin-induced non-insulin- Vagal stimulation 179
Peptidase inhibitor 61 dependent diabetes mellitus rat 315 Vasopressin 61
Phenylephrine 325 Stress-induced analgesia 269 Vasorelaxation 101
Platelet (monkey) 291 Stroke-prone spontaneously hypertensive rat Voltage-clamp 147
Platelet-activating factor 247 39, 351
Propidium iodide 21 Subconjunctival immunization 265 WB4101 ((2-(2,6-dimethoxy-phenoxyethyl)-
Prostacyclin analogue 351 Substance P 281 aminomethyl-1,4-benzodioxane)
Prostaglandin Ej 341 Substance P release 161 hydrochloride) 325
Protein kinase C 175 Supraoptic nucleus 61,73 Whole-cell patch clamp 1
Systemic blood pressure 213
Quinacrine 51 YM022 ((/?)-l-[2,3-dihydro-l-(2'-
Quinolinic acid 183 TA-0910 ((—)-N- [(S)-hexahydro-1 -methy 1- methylphenacyl)-2-oxo-5-phenyl-1 //-1,4-
2,6-dioxo-4-pyrimidinylcarbonyl]-L- benzodiazepin-3-yl]-3-(3-methylphenyl)
Relaxation 167,231 histidyl-L-prolinamide tetrahydrate) 139 urea) 223,307
Renal blood flow 213 Tachykinin 179 YM175 (disodium dihydrogen (cycloheptyl-
Renal kallikrein 11 Taurine 147 amino) methylenebisphosphonate mono¬
Renal secretion 263 Thromboxane 119 hydrate) 239
Thromboxane A2 85
Sarcoplasmic reticulum 337 Thromboxane receptor antagonist 119 Zn-protoporphyrin IX 205
[^H]SCH23390 (/?(-t-)-7-chloro-8-hydroxy-3- Thromboxane synthetase 119
methyl-l-phenyl-2,3,4,5-tetrahydro-l//-3- Thyrotropin-releasing hormone 139
benzazepine) 255 Toxicity 89